Amisty Beck
Primary Care · McAlester, OKNPI 1578791695
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 77 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 19.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $475 and has fallen 90.5% since, to $45 in 2025.
Across 77 payments — averaging $21.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$316
- Seagen Inc.$230
- Sanofi$121
- AbbVie$92
- Takeda Pharmaceuticals U.S.A., Inc.$83
- Pharmacyclics LLC, An Abbvie Company$52
- plus $739 from 27 others
What the payments were for
- Food & beverage$1,62199%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 15 | $316 |
| Seagen Inc. | 8 | $230 |
| Sanofi | 3 | $121 |
| AbbVie | 4 | $92 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $83 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $52 |
| Lilly USA, LLC | 3 | $51 |
| Astellas Pharma US Inc | 3 | $48 |
| Myovant Sciences Inc. | 2 | $46 |
| Daiichi Sankyo Inc. | 2 | $44 |
| Array Biopharma Inc | 3 | $42 |
| Novo Nordisk | 2 | $39 |
| Sobi, Inc | 2 | $37 |
| Puma Biotechnology, Inc. | 2 | $37 |
| Bristol Myers Squibb | 2 | $36 |
| AVEO Pharmaceuticals, Inc. | 1 | $31 |
| Acrotech Biopharma Inc. | 2 | $31 |
| Incyte Corporation | 2 | $30 |
| Merck | 1 | $26 |
| E.r. Squibb & Sons, L.L.C. | 1 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
| Sun Pharmaceutical Industries Inc. | 1 | $20 |
| Agios Pharmaceuticals, Inc. | 1 | $19 |
| Dexcom, Inc. | 1 | $19 |
| Spectrum Pharmaceuticals Inc. | 1 | $17 |
| Novartis | 1 | $17 |
| GSK | 1 | $16 |
| Genentech USA, Inc. | 1 | $16 |
| Pfizer | 1 | $15 |
| Apellis Pharmaceuticals, Inc. | 1 | $14 |
| Amgen | 1 | $14 |
| Heron Therapeutics, Inc. | 1 | $13 |
How this compares
$1,633 in reported general payments places this provider in the 85th percentile of 83 primary care providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Exemestane | 31 | $2,668 |
| Ondansetron OdtOndansetron | 28 | $1,104 |
| Pantoprazole Sodium | 27 | $1,042 |
| Rosuvastatin Calcium | 19 | $637 |
| Anastrozole | 27 | $627 |
| Alendronate Sodium | 49 | $586 |
| Carvedilol | 20 | $565 |
| Levothyroxine Sodium | 79 | $545 |
| Omeprazole | 31 | $515 |
| Gabapentin | 28 | $499 |
| Famotidine | 20 | $372 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 15 | $360 |
| Lisinopril | 28 | $337 |
| Prochlorperazine Maleate | 18 | $308 |
| Tramadol Hcl | 21 | $284 |
Paid to pharmacies, not to this prescriber.
Other primary care in McAlester
- Sammie StoneMcAlester$402
- Amber MaharSallisaw$9K
- Misty DeanOklahoma City$6K
- Melissa GingerichClaremore$6K
- Cristina SarrosaTulsa$6K
- Tamara ManningNorman$5K
- Jessica KearneyOklahoma City$5K
- Erin OlmstedOklahoma City$3K
- Divya JoykuttyOklahoma City$3K
- Stephanie PennieTulsa$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.